+

DK0750668T3 - Nye muteiner af IFN-beta - Google Patents

Nye muteiner af IFN-beta

Info

Publication number
DK0750668T3
DK0750668T3 DK95914045T DK95914045T DK0750668T3 DK 0750668 T3 DK0750668 T3 DK 0750668T3 DK 95914045 T DK95914045 T DK 95914045T DK 95914045 T DK95914045 T DK 95914045T DK 0750668 T3 DK0750668 T3 DK 0750668T3
Authority
DK
Denmark
Prior art keywords
ifn
beta
muteins
those
recombinant dna
Prior art date
Application number
DK95914045T
Other languages
Danish (da)
English (en)
Inventor
Susan E Goelz
Richard L Cate
E Pingchang Chow
R Blake Pepinsky
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DK0750668T3 publication Critical patent/DK0750668T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Amplifiers (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
DK95914045T 1994-03-15 1995-03-13 Nye muteiner af IFN-beta DK0750668T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/213,448 US5545723A (en) 1994-03-15 1994-03-15 Muteins of IFN-β
PCT/US1995/003206 WO1995025170A1 (fr) 1994-03-15 1995-03-13 NOUVELLES MUTEINES D'INTERFERON $g(b)

Publications (1)

Publication Number Publication Date
DK0750668T3 true DK0750668T3 (da) 2009-03-02

Family

ID=22795174

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95914045T DK0750668T3 (da) 1994-03-15 1995-03-13 Nye muteiner af IFN-beta

Country Status (12)

Country Link
US (2) US5545723A (fr)
EP (1) EP0750668B1 (fr)
JP (2) JP3822903B2 (fr)
AT (1) ATE414152T1 (fr)
AU (1) AU695208B2 (fr)
CA (1) CA2185352C (fr)
DE (1) DE69535883D1 (fr)
DK (1) DK0750668T3 (fr)
FI (1) FI120356B (fr)
NO (1) NO318989B1 (fr)
NZ (2) NZ283217A (fr)
WO (1) WO1995025170A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE04266B1 (et) * 1996-12-24 2004-04-15 Biogen, Incorporated Interferooni stabiilne vedelkompositsioon
DK1121382T3 (da) * 1998-10-16 2006-11-13 Biogen Idec Inc Interferon-beta-fusionsproteiner og deres anvendelser
IL142282A0 (en) * 1998-10-16 2002-03-10 Biogen Inc Compositions containing polymer conjugates of interferon-beta-1a
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7144574B2 (en) * 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US7431921B2 (en) * 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
US20010043915A1 (en) * 1999-12-09 2001-11-22 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
ATE432288T1 (de) 2001-02-27 2009-06-15 Maxygen Aps Neue interferon-beta-ähnliche moleküle
US20030091544A1 (en) * 2001-03-13 2003-05-15 Vical Incorporated Interferon-Beta polynucleotide therapy for autoimmune and inflammatory diseases
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
EP1435979A4 (fr) * 2001-09-18 2008-01-23 Novartis Vaccines & Diagnostic Methodes de traitement de la sclerose en plaques
IL161251A0 (en) 2001-10-10 2004-09-27 Neose Technologies Inc Remodeling and glycoconjugation of peptides
WO2004022593A2 (fr) * 2002-09-09 2004-03-18 Nautilus Biotech Evolution rationnelle de cytokines pour une plus grande stabilite, les cytokines et molecules d'acide nucleique codant
RS20050255A (en) * 2002-09-27 2007-08-03 Biogen Idec Ma Inc., Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-betha
AU2003277088A1 (en) * 2002-10-01 2004-04-23 Xencor, Inc Interferon variants with improved properties
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
CA2522345A1 (fr) 2003-04-09 2004-11-18 Neose Technologies, Inc. Methode de glycopegylation et proteines/peptides produits au moyen de ces methodes
KR20060130182A (ko) 2004-02-02 2006-12-18 암브룩스, 인코포레이티드 변형된 인간 인터페론 폴리펩티드 및 이의 용도
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
DOP2006000116A (es) * 2005-05-19 2007-01-31 Schering Ag Sistema mejorado de expresión regulada y sus usos.
US20080076729A1 (en) * 2005-05-19 2008-03-27 Schering Aktiengesellachaft Interferon-beta gene therapy using an improved, regulated expression system
US20070179113A1 (en) * 2005-05-19 2007-08-02 Schering Aktiengesellachaft GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
EP1891224A1 (fr) * 2005-05-19 2008-02-27 Bayer Schering Pharma Aktiengesellschaft Therapie genique a base d'interferons beta utilisant un systeme d'expression regulee, ameliore
KR101276367B1 (ko) * 2005-08-26 2013-06-25 아레스 트레이딩 에스.에이. 당화된 인터페론 베타를 제조하기 위한 방법
WO2007110231A2 (fr) * 2006-03-28 2007-10-04 Nautilus Biotech, S.A. POLYPEPTIDES D'INTERFÉRON-β (IFN-β) MODIFIÉS
WO2008125222A2 (fr) * 2007-04-11 2008-10-23 Bayer Schering Pharma Aktiengesellschaft Nouvelles molécules de modulation destinées à un système d'expression régulée amélioré
US20100196328A1 (en) * 2007-04-25 2010-08-05 Tonya Bliss ISCHEMIA-INDUCED NEOVASCULARIZATION IS ENHANCED BY hCNS-SC TRANSPLANTATION
MX2009011870A (es) * 2007-05-02 2009-11-12 Ambrx Inc Polipeptidos de interferon beta modificados y usos de los mismos.
US8273561B2 (en) * 2007-10-05 2012-09-25 Nuron Biotech, Inc. High pressure treatment of aggregated interferons
EP2379711B8 (fr) * 2008-12-23 2017-03-22 BOCO Silicon Valley, Inc. Populations cibles de cellules précurseurs d'oligodendrocytes et leurs méthodes de fabrication et d'utilisation
WO2019073315A1 (fr) 2017-10-09 2019-04-18 Mansour Poorebrahim Peptide analogue d'interféron-bêta

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341604C (fr) * 1980-04-03 2010-05-04 Biogen N.V. Sequences d'adn, molecules d'adn recombine, ainsi que des procedes pour produire des polypeptides de fibroblastes humaine semblables a l'interferon
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
IE56026B1 (en) * 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
GB8317880D0 (en) * 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
GB8334102D0 (en) * 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4816440A (en) * 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
DE3683910D1 (de) * 1986-09-05 1992-03-26 Cetus Corp Oxidationsresistente muteine von beta-interferon, deren herstellung und diese muteine enthaltende praeparate.
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
IL92124A (en) * 1988-10-28 1996-10-31 Sidney Pestka Recombinant proteins modified to contain post-phosphorylation that do not occur in nature
WO1993015609A1 (fr) * 1992-02-05 1993-08-19 Thomas Jefferson University Therapie genique par interferons pour le traitement des pathologies vasculaires

Also Published As

Publication number Publication date
CA2185352A1 (fr) 1995-09-21
FI963630A7 (fi) 1996-09-13
NZ283217A (en) 1998-05-27
WO1995025170A1 (fr) 1995-09-21
ATE414152T1 (de) 2008-11-15
NO963837D0 (no) 1996-09-13
JP2006199711A (ja) 2006-08-03
JPH10500563A (ja) 1998-01-20
EP0750668B1 (fr) 2008-11-12
FI963630A0 (fi) 1996-09-13
MX9604073A (es) 1997-12-31
NO963837L (no) 1996-11-14
US6127332A (en) 2000-10-03
AU695208B2 (en) 1998-08-06
DE69535883D1 (de) 2008-12-24
CA2185352C (fr) 2005-02-22
NZ329970A (en) 2000-01-28
JP3822903B2 (ja) 2006-09-20
AU2120295A (en) 1995-10-03
EP0750668A1 (fr) 1997-01-02
FI120356B (fi) 2009-09-30
US5545723A (en) 1996-08-13
NO318989B1 (no) 2005-05-30

Similar Documents

Publication Publication Date Title
DK0750668T3 (da) Nye muteiner af IFN-beta
DK75694A (da) Tumornecrosefaktor og derivater og mutantformer deraf, fremgangsmåde til fremstilling deraf, DNA som koder derfor, replicerbar udtrykkelsesvektor indeholdende DNA'en og celle transformeret dermed samt præparater omfattende tumornecrosefaktoren
NO914541L (no) Fremgangsmaate ved fremstilling av tumor-nekrose-faktor-muteiner
DK0880970T3 (da) Anvendelse af farmaceutiske præparater der omfatter et anticytokin, til behandling af dissemineret sklerose
NO931141L (no) Tnf-muteiner
RU95115239A (ru) Аналог эритропоэтина
WO1995025170B1 (fr) NOUVELLES MUTEINES D'INTERFERON $g(b)
WO2002074980A3 (fr) Muteines du facteur de transcription alpha inductible en hypoxie
ATE91630T1 (de) Pharmazeutische zusammensetzung zur verhuetung oder heilung von durch den papillomavirus induzierten tumoren.
NO984551L (no) Modulatorer av TNF-receptorforbundet faktor (TRAF), deres fremstilling og anvendelse
EP0592566A4 (fr) Muteines d'il-6 depourvues de cysteine-------------.
ATE128728T1 (de) Interferon-gamma bindende proteine.
DE3788899D1 (de) Intraläsionale Behandlung von Basalzellenkarzinoma mittels rekombinanten humanen alpha-Interferons.
DE59208025D1 (de) Neue thrombininhibitorische proteine aus landblutegeln
IT1262545B (it) Sistema di espressione per linee cellulari eucariotiche
MY107071A (en) Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
DE68918399D1 (de) Lymphokine, DNS-Sequenzen, die diese Lymphokine kodieren, und sie enthaltende pharmazeutische Zusammensetzungen.
GR3025841T3 (en) An anti-hiv protein, tap 29, from trichosanthes, dna coding therefor and therapeutic uses thereof
Goelz et al. Muteins of IFN-beta
Yamaguchi et al. A procedure for the purification of ferritin using Matrex Red A
ATE386803T1 (de) Intrazelluläre glukocortikoid-induzierte leucin- zipper modulatoren von mechanismen des apoptotischen zelltodes
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载